Eli Lilly and Company (NYSE: LLY) has announced the appointment of Thomas J. Fuchs, Dr.sc., as its first chief AI officer, effective from October 21, 2024. Fuchs will be responsible for providing strategic direction and leadership for AI initiatives across the company, including drug discovery, clinical trials, manufacturing, and commercial activities. He will also manage AI and machine learning solutions to support Lilly’s mission to deliver medicines globally.
Fuchs joins Lilly from a diverse background that includes serving as the dean and inaugural department chair for AI and Human Health at Mount Sinai, director of the Hasso Plattner Institute for Digital Health at Mount Sinai, and the endowed Barbara T. Murphy professor for AI and computational pathology at the Icahn School of Medicine at Mount Sinai. He has previously held positions at Memorial Sloan Kettering Cancer Center, NASA’s Jet Propulsion Laboratory, and the California Institute of Technology, and has founded three companies, including Paige AI. Fuchs holds a doctoral degree in machine learning from ETH Zurich and a master’s in technical mathematics from Graz Technical University in Austria. – Flcube.com
